C4 Therapeutics, Inc.
CCCC
$2.61
-$0.08-2.97%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.02% | -10.57% | 16.55% | 98.56% | 71.44% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.02% | -10.57% | 16.55% | 98.56% | 71.44% |
| Cost of Revenue | -28.41% | -87.40% | -81.41% | -84.64% | -89.35% |
| Gross Profit | 17.03% | 121.96% | 119.46% | 124.91% | 123.77% |
| SG&A Expenses | -14.07% | -11.08% | -1.41% | -0.62% | 0.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.07% | -0.93% | 8.24% | 2.44% | -4.40% |
| Operating Income | 10.83% | -1.85% | -6.15% | 12.09% | 15.72% |
| Income Before Tax | 0.30% | -13.05% | -4.56% | 17.35% | 19.84% |
| Income Tax Expenses | -7.63% | -52.71% | -89.77% | -89.77% | -89.77% |
| Earnings from Continuing Operations | 0.31% | -12.88% | -3.44% | 18.08% | 20.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.31% | -12.88% | -3.44% | 18.08% | 20.51% |
| EBIT | 10.83% | -1.85% | -6.15% | 12.09% | 15.72% |
| EBITDA | 11.12% | -1.66% | -6.05% | 12.28% | 15.89% |
| EPS Basic | 10.50% | 1.95% | 16.71% | 37.95% | 43.20% |
| Normalized Basic EPS | 19.64% | 9.80% | 14.43% | 35.05% | 43.04% |
| EPS Diluted | 10.50% | 1.95% | 16.71% | 37.95% | 43.20% |
| Normalized Diluted EPS | 19.64% | 9.80% | 14.43% | 35.05% | 43.04% |
| Average Basic Shares Outstanding | 19.36% | 10.42% | 18.66% | 28.41% | 39.74% |
| Average Diluted Shares Outstanding | 19.36% | 10.42% | 18.66% | 28.41% | 39.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |